-
1
-
-
0030897009
-
International scoring system for evaluating prognosis in myelodysplastic syndromes
-
Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 88-2079
-
(1997)
Blood
, vol.89
, pp. 88-2079
-
-
Greenberg, P.1
Cox, C.2
LeBeau, M.M.3
-
2
-
-
0029020851
-
Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
-
Raza A., Gezer S., Mundle S., et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86 (1995) 76-268
-
(1995)
Blood
, vol.86
, pp. 76-268
-
-
Raza, A.1
Gezer, S.2
Mundle, S.3
-
3
-
-
0029957664
-
Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
-
Rajapaksa R., Ginzton N., Rott L.S., and Greenberg P.L. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88 (1996) 84-4275
-
(1996)
Blood
, vol.88
, pp. 84-4275
-
-
Rajapaksa, R.1
Ginzton, N.2
Rott, L.S.3
Greenberg, P.L.4
-
4
-
-
0030926080
-
Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes
-
Bouscary D., De Vos J., Guesnu M., et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 11 (1997) 45-839
-
(1997)
Leukemia
, vol.11
, pp. 45-839
-
-
Bouscary, D.1
De Vos, J.2
Guesnu, M.3
-
5
-
-
0035146787
-
Excessive apoptosis in low risk myelodysplastic syndromes (MDS)
-
Parker J.E., and Mufti G.J. Excessive apoptosis in low risk myelodysplastic syndromes (MDS). Leuk Lymphoma 40 (2000) 1-24
-
(2000)
Leuk Lymphoma
, vol.40
, pp. 1-24
-
-
Parker, J.E.1
Mufti, G.J.2
-
6
-
-
0036848438
-
More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia
-
Huh Y.O., Jilani I., Estey E., et al. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. Leukemia 16 (2002) 52-2249
-
(2002)
Leukemia
, vol.16
, pp. 52-2249
-
-
Huh, Y.O.1
Jilani, I.2
Estey, E.3
-
7
-
-
0027086859
-
Measurement of serum cytokine levels in patients with myelodysplastic syndromes
-
Verhoef G.E., De Schouwer P., Ceuppens J.L., Van Damme J., Goossens W., and Boogaerts M.A. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 6 (1992) 72-1268
-
(1992)
Leukemia
, vol.6
, pp. 72-1268
-
-
Verhoef, G.E.1
De Schouwer, P.2
Ceuppens, J.L.3
Van Damme, J.4
Goossens, W.5
Boogaerts, M.A.6
-
8
-
-
28044465152
-
Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis
-
Stifter G., Heiss S., Gastl G., Tzankov A., and Stauder R. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol 75 (2005) 91-485
-
(2005)
Eur J Haematol
, vol.75
, pp. 91-485
-
-
Stifter, G.1
Heiss, S.2
Gastl, G.3
Tzankov, A.4
Stauder, R.5
-
9
-
-
0031656518
-
A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome
-
Gersuk G.M., Beckham C., Loken M.R., et al. A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 103 (1998) 88-176
-
(1998)
Br J Haematol
, vol.103
, pp. 88-176
-
-
Gersuk, G.M.1
Beckham, C.2
Loken, M.R.3
-
10
-
-
0037388243
-
Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases
-
Sashida G., Ohyashiki J.H., Nakajima A., et al. Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases. Clin Cancer Res 9 (2003) 96-1489
-
(2003)
Clin Cancer Res
, vol.9
, pp. 96-1489
-
-
Sashida, G.1
Ohyashiki, J.H.2
Nakajima, A.3
-
11
-
-
85046523148
-
Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia
-
Kurotaki H., Tsushima Y., Nagai K., and Yagihashi S. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol 102 (2000) 23-115
-
(2000)
Acta Haematol
, vol.102
, pp. 23-115
-
-
Kurotaki, H.1
Tsushima, Y.2
Nagai, K.3
Yagihashi, S.4
-
12
-
-
0020574146
-
Use of bone marrow culture in prediction of acute leukaemic transformation in pre-leukaemia
-
Francis G.E., Wing M.A., Miller E.J., Berney J.J., Wonke B., and Hoffbrand A.V. Use of bone marrow culture in prediction of acute leukaemic transformation in pre-leukaemia. Lancet I (1983) 12-1409
-
(1983)
Lancet
, vol.I
, pp. 12-1409
-
-
Francis, G.E.1
Wing, M.A.2
Miller, E.J.3
Berney, J.J.4
Wonke, B.5
Hoffbrand, A.V.6
-
13
-
-
0037111548
-
Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression
-
Kochenderfer J.N., Kobayashi S., Wieder E.D., Su C., and Molldrem J.J. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 100 (2002) 45-639
-
(2002)
Blood
, vol.100
, pp. 45-639
-
-
Kochenderfer, J.N.1
Kobayashi, S.2
Wieder, E.D.3
Su, C.4
Molldrem, J.J.5
-
14
-
-
0036229652
-
A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome
-
Maciejewski J.P., Risitano A.M., Sloand E.M., et al. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol 117 (2002) 26-119
-
(2002)
Br J Haematol
, vol.117
, pp. 26-119
-
-
Maciejewski, J.P.1
Risitano, A.M.2
Sloand, E.M.3
-
15
-
-
0036174925
-
Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes
-
Stasi R., and Amadori S. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol 116 (2002) 7-334
-
(2002)
Br J Haematol
, vol.116
, pp. 7-334
-
-
Stasi, R.1
Amadori, S.2
-
16
-
-
0030695069
-
Antithymocyte globulin for patients with myelodysplastic syndrome
-
Molldrem J.J., Caples M., Mavroudis D., Plante M., Young N.S., and Barrett A.J. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 99 (1997) 699-705
-
(1997)
Br J Haematol
, vol.99
, pp. 699-705
-
-
Molldrem, J.J.1
Caples, M.2
Mavroudis, D.3
Plante, M.4
Young, N.S.5
Barrett, A.J.6
-
17
-
-
0037031289
-
Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes
-
Molldrem J.J., Leifer E., Bahceci E., et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 137 (2002) 63-156
-
(2002)
Ann Intern Med
, vol.137
, pp. 63-156
-
-
Molldrem, J.J.1
Leifer, E.2
Bahceci, E.3
-
18
-
-
0345701967
-
A pilot study of antithymocyte globulin (ATG) in the treatment of patients with low-risk' myelodysplasia
-
Killick S.B., Mufti G., Cavenagh J.D., et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with low-risk' myelodysplasia. Br J Haematol 120 (2003) 84-679
-
(2003)
Br J Haematol
, vol.120
, pp. 84-679
-
-
Killick, S.B.1
Mufti, G.2
Cavenagh, J.D.3
-
19
-
-
1542608520
-
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes
-
Stadler M., Germing U., Kliche K.O., et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18 (2004) 5-460
-
(2004)
Leukemia
, vol.18
, pp. 5-460
-
-
Stadler, M.1
Germing, U.2
Kliche, K.O.3
-
20
-
-
0031888417
-
Ciclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow
-
Janasova A., Neuwirtova R., Cermak J., et al. Ciclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 100 (1998) 9-304
-
(1998)
Br J Haematol
, vol.100
, pp. 9-304
-
-
Janasova, A.1
Neuwirtova, R.2
Cermak, J.3
-
21
-
-
0242643661
-
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes
-
Yazji S., Giles F.J., Tsimberidou A.M., et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 17 (2003) 6-2101
-
(2003)
Leukemia
, vol.17
, pp. 6-2101
-
-
Yazji, S.1
Giles, F.J.2
Tsimberidou, A.M.3
-
22
-
-
33744492061
-
Antithymocyte globulin and ciclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes
-
Broliden P.A., Dahl I.M., Hast R., et al. Antithymocyte globulin and ciclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 91 (2006) 70-667
-
(2006)
Haematologica
, vol.91
, pp. 70-667
-
-
Broliden, P.A.1
Dahl, I.M.2
Hast, R.3
-
23
-
-
33745968917
-
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
-
Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108 (2006) 25-419
-
(2006)
Blood
, vol.108
, pp. 25-419
-
-
Cheson, B.D.1
Greenberg, P.L.2
Bennett, J.M.3
-
24
-
-
0037443455
-
Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome
-
Steensma D.P., Dispenzieri A., Moore S.B., Schroeder G., and Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 101 (2003) 2156-2158
-
(2003)
Blood
, vol.101
, pp. 2156-2158
-
-
Steensma, D.P.1
Dispenzieri, A.2
Moore, S.B.3
Schroeder, G.4
Tefferi, A.5
-
25
-
-
7344223859
-
Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles
-
Molldrem J.J., Jiang Y.Z., Stetler-Stevenson M., Mavroudis D., Hensel N., and Barrett A.J. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102 (1998) 22-1314
-
(1998)
Br J Haematol
, vol.102
, pp. 22-1314
-
-
Molldrem, J.J.1
Jiang, Y.Z.2
Stetler-Stevenson, M.3
Mavroudis, D.4
Hensel, N.5
Barrett, A.J.6
-
26
-
-
0034037280
-
Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia
-
Killick S.B., Marsh J.C., Gordon-Smith E.C., Sorlin L., and Gibson F.M. Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia. Br J Haematol 108 (2000) 91-582
-
(2000)
Br J Haematol
, vol.108
, pp. 91-582
-
-
Killick, S.B.1
Marsh, J.C.2
Gordon-Smith, E.C.3
Sorlin, L.4
Gibson, F.M.5
-
27
-
-
20244381363
-
Favourable resopnse to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a,,non-clonal" pattern of X-chromosome inactivation in bone marrow cells
-
Aivado M., Rong A., Stadler M., et al. Favourable resopnse to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a,,non-clonal" pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 68 (2002) 6-210
-
(2002)
Eur J Haematol
, vol.68
, pp. 6-210
-
-
Aivado, M.1
Rong, A.2
Stadler, M.3
-
28
-
-
0036720903
-
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromes
-
Saunthararajah Y., Nakamura R., Nam J.M., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromes. Blood 100 (2002) 4-1570
-
(2002)
Blood
, vol.100
, pp. 4-1570
-
-
Saunthararajah, Y.1
Nakamura, R.2
Nam, J.M.3
-
29
-
-
0141923848
-
A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndromes
-
Saunthararajah Y., Nakamura R., Wesley R., and Barrett A.J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndromes. Blood 102 (2003) 7-3025
-
(2003)
Blood
, vol.102
, pp. 7-3025
-
-
Saunthararajah, Y.1
Nakamura, R.2
Wesley, R.3
Barrett, A.J.4
-
30
-
-
0037353935
-
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life
-
Hellström-Lindberg E., Gulbrandsen N., Lindberg G., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120 (2003) 46-1037
-
(2003)
Br J Haematol
, vol.120
, pp. 46-1037
-
-
Hellström-Lindberg, E.1
Gulbrandsen, N.2
Lindberg, G.3
-
31
-
-
33749438404
-
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
-
List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355 (2006) 65-1456
-
(2006)
N Engl J Med
, vol.355
, pp. 65-1456
-
-
List, A.1
Dewald, G.2
Bennett, J.3
-
32
-
-
0023878418
-
Antilymphocyte globulin for myelodysplastic syndrome
-
Tichelli A., Gratwohl A., Wuersch A., Nissen C., and Speck B. Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol 68 (1988) 40-139
-
(1988)
Br J Haematol
, vol.68
, pp. 40-139
-
-
Tichelli, A.1
Gratwohl, A.2
Wuersch, A.3
Nissen, C.4
Speck, B.5
|